Stock Ticker

Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil

Competing interests

The authors report the following conflicts of interest: Dr. Hamilton reports (ad hoc) advisory boards for Sanofi, Incyte, Maat; research funding from Incyte; adjudication committee with CSL Behring. The remaining authors have no relevant disclosures to report.

Ethics approval and consent to participate

This study was approved by the Cleveland Clinic Institutional Review Board, which deemed this study minimal risk research not requiring informed consent. All methods were performed in compliance with the relevant regulations, including the Declaration of Helsinki. No identifiable patient details are presented in this manuscript.

Source link

Get RawNews Daily

Stay informed with our RawNews daily newsletter email

Liverpool defender left out of World Cup squad

Madonna Covering Rent For Musicians Working At Her Old NYC Rehearsal Space

Up 16.5%! Here’s why Hollywood Bowl stock smashed the FTSE 250 today

Trump says Iran would not get sanctions relief in exchange for giving up enriched uranium